Maramattom Boby Varkey
Neurology, Aster Medcity, Kochi, IND.
Cureus. 2022 Mar 15;14(3):e23197. doi: 10.7759/cureus.23197. eCollection 2022 Mar.
ChAdOx1 nCoV-19 vaccine (AstraZeneca) has been associated with rare adverse events following vaccination such as thrombosis with thrombocytopenia syndrome, inflammatory myositis, and autoimmune encephalitis. Para-infectious or post-infectious myelin oligodendrocyte glycoprotein-associated disorders (MOGAD) have been reported in association with coronavirus disease. However, post-vaccine MOGAD (PV-MOGAD) has not yet been reported. Here, we report three cases of PV-MOGAD who presented with a prolonged severe headache after the ChAdOx1 vaccination. Other features of MOGAD such as optic neuritis or tumefactive demyelination appeared much later. Aseptic meningitis can be a presenting feature of PV-MOGAD. When patients present with a severe headache after the ChAdOx1 vaccination, PV-MOGAD should be considered along with thrombosis with thrombocytopenia syndrome.
ChAdOx1 nCoV-19疫苗（阿斯利康）与接种疫苗后出现的罕见不良事件有关，如伴有血小板减少的血栓形成综合征、炎性肌炎和自身免疫性脑炎。与冠状病毒病相关的副感染性或感染后髓鞘少突胶质细胞糖蛋白相关疾病（MOGAD）已有报道。然而，疫苗接种后MOGAD（PV-MOGAD）尚未见报道。在此，我们报告3例PV-MOGAD病例，这些患者在接种ChAdOx1疫苗后出现了持续的严重头痛。MOGAD的其他特征，如视神经炎或瘤样脱髓鞘，出现得要晚得多。无菌性脑膜炎可能是PV-MOGAD的一个表现特征。当患者在接种ChAdOx1疫苗后出现严重头痛时，应考虑PV-MOGAD以及伴有血小板减少的血栓形成综合征。
